In a live event, Ganesh V. Raj, MD, PhD, discussed the drug-drug interactions and outcomes by disease volumes across ARPI ...

The first clinical trial under the Cooperative Research and Development Agreement with the National Cancer Institute and ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of multiple myeloma after quadruplet frontline with transplant.

A panelist discusses how community practitioners should monitor for immune-related adverse events when using toripalimab for recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC), establish clear ...

A panelist discusses A panelist discusses how the integration of immunotherapy with chemotherapy as first-line treatment for recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC) is transforming ...

A panelist discusses how low baseline EBV levels still showed benefit from toripalimab in JUPITER-02, though EBV status influences treatment decisions and alternative markers are needed for ...

A panelist discusses how the unclear request format creates ambiguity about which case is being referenced, making it difficult to provide specific details that stand out without additional context.

Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder cancer space and data from several ...

An expanded access program evaluating cretostimogene grenadenorepvec was highlighted during the 25th Annual Meeting of the ...

An expert discusses how adjuvant therapy options for high-risk muscle-invasive bladder cancer (MIBC); ypT2-ypT4a or N+) ...

An expert discusses how patients with muscle-invasive urothelial carcinoma (MIUC) undergoing radical cystectomy face a ...